GHRP-2 vs GHRP-6
Two first-generation ghrelin-receptor peptides. GHRP-2 is the more characterized and more aggressive releaser; GHRP-6 is the one defined by how hungry it makes you.
Short answer
Both have human clinical data behind them, which makes the goal the real difference between GHRP-2 and GHRP-6. For a reader focused on muscle, GHRP-2 is the relevant choice; GHRP-6 is marketed for muscle and recovery. For GHRP-2, five days of daily injections in healthy men did not raise IGF-1, and the GH response faded.
GHRP-2
Pralmorelin
Genuinely raises GH (and is an approved diagnostic in Japan), but the same dose lifts cortisol, prolactin and appetite, and desensitizes — no anti-aging outcomes.
Full GHRP-2 evidence reviewGHRP-6
Pulses GH short-term, but its most reliable real-world effect is a surge in appetite; no long-term human outcomes and not approved.
Full GHRP-6 evidence reviewGHRP-2 vs GHRP-6: head to head
- FDA status / approved use
GHRP-2
Approved in Japan only as a growth-hormone diagnostic; not FDA-approved; sold as gray-market research peptideGHRP-6
Not FDA-approved; sold as a gray-market research peptide- Marketed for
GHRP-2
Muscle, 'anti-aging'GHRP-6
Muscle, recovery, 'anti-aging'- Outcome areas
GHRP-2
Muscle / strength / lean mass; Longevity / lifespanGHRP-6
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan- Evidence grade
GHRP-2
Clinical dataGHRP-6
Clinical data- How it works
GHRP-2
Activates the ghrelin receptor to trigger a pulse of growth hormone from the pituitaryGHRP-6
Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone- Route and dosing
GHRP-2
Subcutaneous injectionGHRP-6
Injection, usually subcutaneous; also studied intravenous and oral- Headline human result
GHRP-2
Five days of daily injections in healthy men did not raise IGF-1, and the GH response fadedGHRP-6
GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data- Strongest evidence
GHRP-2
Bowers, Endocrine 2001GHRP-2 evidence reviewPubMed 11322505GHRP-6
Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313- Key safety signal
GHRP-2
Also raises cortisol, ACTH and prolactin and increases appetiteGHRP-6
Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing- How it is obtained
GHRP-2
Sold gray-market as a research chemical; no approved or legitimately compounded human productGHRP-6
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| GHRP-2 | GHRP-6 | |
|---|---|---|
| FDA status / approved use | Approved in Japan only as a growth-hormone diagnostic; not FDA-approved; sold as gray-market research peptide | Not FDA-approved; sold as a gray-market research peptide |
| Marketed for | Muscle, 'anti-aging' | Muscle, recovery, 'anti-aging' |
| Outcome areas | Muscle / strength / lean mass; Longevity / lifespan | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Activates the ghrelin receptor to trigger a pulse of growth hormone from the pituitary | Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone |
| Route and dosing | Subcutaneous injection | Injection, usually subcutaneous; also studied intravenous and oral |
| Headline human result | Five days of daily injections in healthy men did not raise IGF-1, and the GH response faded | GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data |
| Strongest evidence | Bowers, Endocrine 2001GHRP-2 evidence reviewPubMed 11322505 | Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313 |
| Key safety signal | Also raises cortisol, ACTH and prolactin and increases appetite | Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
GHRP-2 has the stronger human record: reproducible acute GH increases, a multicenter stimulation-test study, and diagnostic approval in Japan. GHRP-6's human data is older but real, showing GH release across intravenous, subcutaneous, intranasal and oral routes. Both come bundled with adrenal spillover, with GHRP-2 generally regarded as the more aggressive ACTH and cortisol releaser, and both drive appetite; GHRP-6's orexigenic effect is its signature. Neither is approved for body composition or anti-aging, both are sold as gray-market research peptides, and no multi-week outcome trials have been run for either.
GHRP-2 fits if
GHRP-2 fits the reader who wants the best-documented GHRP, particularly its validated role as a short-acting probe of pituitary GH output.
GHRP-6 fits if
GHRP-6 is the one to study if you are interested in ghrelin-driven appetite biology or the preclinical cytoprotection thread, keeping in mind its wound and heart findings are rodent-level.
GHRP-2 vs GHRP-6: common questions
- Is either GHRP-2 or GHRP-6 FDA-approved?
- No. GHRP-2 is approved in Japan only as a growth-hormone diagnostic; not FDA-approved; sold as gray-market research peptide. GHRP-6 is not FDA-approved; sold as a gray-market research peptide.
- Which has stronger human evidence, GHRP-2 or GHRP-6?
- Neither clearly. Both have human clinical data. The key source for GHRP-2 is Bowers, Endocrine 2001; for GHRP-6, it is Jaffe, JCEM 1993.
- What are the main safety concerns with GHRP-2 and GHRP-6?
- GHRP-2 also raises cortisol, ACTH and prolactin and increases appetite. For GHRP-6, watch for strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing.
Key studies behind each
GHRP-2
- Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. PubMed 9285939
- Bowers CY, Granda-Ayala R. (2001). Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. PubMed 11322505
- Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y; KP-102 Study Group. (2007). A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. PubMed 17609397
- Laferrère B, Abraham C, Russell CD, Bowers CY. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. PubMed 15699539
GHRP-6
- Frieboes RM, Murck H, Maier P, et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. PubMed 7617137
- Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993). Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. PubMed 7903313
- Frieboes RM, Murck H, Antonijevic IA, et al. (1999). Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. PubMed 10336729
- Bellone J, Ghizzoni L, Aimaretti G, et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. PubMed 7581965
The full evidence reviews
- GHRP-2: a real GH secretagogue, marketed for things it hasn't been shown to do
GHRP-2 (pralmorelin) genuinely raises growth hormone and is an approved diagnostic agent in Japan — but the same dose lifts cortisol, ACTH and prolactin, drives appetite, and desensitizes with daily use. A straight read of the human data behind the anti-aging marketing.
Updated August 2026
- GHRP-6: the 'hunger' growth-hormone secretagogue, and what the evidence shows
GHRP-6 is a first-generation ghrelin-receptor agonist that pulses growth hormone — but its most reliable real-world effect is a strong, dose-dependent surge in appetite. Real short-term GH pharmacology, preclinical cytoprotection, no long-term human outcomes, and not FDA-approved.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-2 availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: HealthSourceHelloWellnessHeva HealthImmortalsLumoraLunaRx